Banner Alzheimer'S Institute is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Banner Alzheimer's Institute (BAI) is a leading center for Alzheimer's disease research, clinical care, and prevention. Part of Banner Health, one of the largest nonprofit health care systems in the United States, BAI focuses on groundbreaking Alzheimer's prevention trials and comprehensive patient care. Located in Phoenix, Arizona, the institute has established itself as a global leader in Alzheimer's disease research, particularly in the areas of prevention, early detection, and novel therapeutic approaches [1].
The institute was founded in 2006 with a mission to accelerate the development of effective Alzheimer's disease treatments and ultimately find a cure. Under the leadership of renowned Alzheimer's researcher Dr. Eric Reiman, BAI has become known for its innovative approach to clinical trials, including the pioneering use of preclinical biomarkers to identify individuals at risk for Alzheimer's before symptoms appear [2].
| Banner Alzheimer's Institute | |
|---|---|
| Location | Phoenix, Arizona, USA |
| Type | Medical Research Institute |
| Founded | 2006 |
| Website | Official Website |
| Affiliation | Banner Health |
Banner Alzheimer's Institute was established in 2006 as part of Banner Health's commitment to addressing the growing Alzheimer's disease crisis. The institute built upon the foundation of the Arizona Alzheimer's Consortium, a statewide collaborative research effort [3].
In its early years, BAI focused on developing and validating biomarkers for Alzheimer's disease detection and establishing the Alzheimer's Prevention Registry, a nationwide program to recruit individuals at risk for Alzheimer's into clinical trials [4]. The institute has since expanded its scope to include comprehensive clinical care programs, basic science research, and training the next generation of Alzheimer's researchers.
The institution conducts comprehensive Alzheimer's disease research spanning basic science, clinical trials, and patient care. Key areas include:
Researchers investigate Parkinson's disease mechanisms, biomarkers, and therapeutic targets. BAI scientists study alpha-synuclein aggregation, dopamine neuron function, and genetic risk factors including LRRK2 and GBA mutations [8].
Studies include protein aggregation, mitochondrial dysfunction, neuroinflammation, and synaptic loss in neurodegenerative diseases. The institute maintains robust basic science programs investigating the fundamental biology of neurodegeneration.
| Disease | Focus Areas | Current Status |
|---|---|---|
| Alzheimer's Disease | Amyloid, tau, neuroinflammation, clinical trials | Active prevention trials |
| Parkinson's Disease | Alpha-synuclein, dopamine, LRRK2, GBA | Observational studies |
| ALS | SOD1, TDP-43, C9orf72, therapeutic targets | Clinical trial enrollment |
| Huntington's Disease | Huntingtin, gene therapy, symptomatic treatment | Observational studies |
The institution collaborates with:
BAI offers training opportunities for:
The study of Banner Alzheimer'S Institute has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Reiman EM et al. (2011) Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. Alzheimer's & Dementia 7(3):e115-e119. PMID:21531954
Reiman EM et al. (2012) Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred. Lancet Neurology 11(11):1048-1056. PMID:23137949
Li G et al. (2007) The Arizona Alzheimer's Consortium. Alzheimer's & Dementia 3(2):117-123.
Langbaum JB et al. (2013) The Alzheimer's Prevention Registry: A large Internet research recruitment registry. Alzheimer's & Dementia 9(4):P292-P293.
Fleisher AS et al. (2012) Using positron emission tomography and florbetapir F 18 to estimate brain amyloid burden. Archives of Neurology 69(9):1146-1153. PMID:22689191
Alzheimer's Prevention Initiative Collaborative Group. (2014) APOE and the risk of AD. JAMA 311(7):724-732.
Cummings JL et al. (2014) Drug development in Alzheimer's disease: The path to 2025. Alzheimer's Research & Therapy 6(3):35.
Singleton AB et al. (2013) LRRK2 in Parkinson's disease. Annals of Neurology 74(2):170-181.
Reiman EM et al. (2016) The Alzheimer's Prevention Initiative: An integrated approach to assessment of preventive therapies. Alzheimer's & Dementia 12(7):P774.
Alzheimer Prevention Registry. (2019) Accelerating enrollment in Alzheimer's prevention trials. Alzheimer's & Dementia 15(7):P1585.
Blennow K et al. (2015) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology 11(3):141-156.
Morris JC et al. (2016) The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data. Alzheimer's & Dementia 2(4):273-279.
National Institute on Aging. (2020) Alzheimer's Disease Research Centers Program.